{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:06:18Z","timestamp":1784725578839,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncolytics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.omto.2021.01.012","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T21:54:25Z","timestamp":1611611665000},"page":"387-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Adoptive T\u00a0cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4"],"prefix":"10.1016","volume":"20","author":[{"given":"Vijay G.","family":"Bhoj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Parvathaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Kacir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Arhontoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bevin","family":"McGettigan-Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Nunez-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Gulendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina C.","family":"Boesteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MacLean","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Goydel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don L.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2021.01.012_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","article-title":"Medullary thyroid carcinoma","volume":"22","author":"Pacini","year":"2010","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.omto.2021.01.012_bib2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1634\/theoncologist.2013-0053","article-title":"Current understanding and management of medullary thyroid cancer","volume":"18","author":"Roy","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.omto.2021.01.012_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ctrv.2016.09.006","article-title":"Systemic treatment and management approaches for medullary thyroid cancer","volume":"50","author":"Ernani","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.omto.2021.01.012_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpendmet0717","article-title":"New therapeutic approaches to treat medullary thyroid carcinoma","volume":"4","author":"Schlumberger","year":"2008","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.omto.2021.01.012_bib5","doi-asserted-by":"crossref","first-page":"R215","DOI":"10.1530\/EJE-14-0788","article-title":"Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis","volume":"172","author":"Klein Hesselink","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.omto.2021.01.012_bib6","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.01.012_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.01.012_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The Pharmacology of T Cell Therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omto.2021.01.012_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omto.2021.01.012_bib10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.01.012_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.01.012_bib12","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2018.01740","article-title":"CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies","volume":"9","author":"Knochelmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2021.01.012_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CAR-T therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omto.2021.01.012_bib14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T\u00a0cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.01.012_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mcne.1999.0754","article-title":"GDNF family neurotrophic factor signaling: four masters, one servant?","volume":"13","author":"Airaksinen","year":"1999","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.omto.2021.01.012_bib16","doi-asserted-by":"crossref","first-page":"9344","DOI":"10.1074\/jbc.M008279200","article-title":"Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells","volume":"276","author":"Lindahl","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omto.2021.01.012_bib17","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1210\/en.2005-1620","article-title":"Ablation of persephin receptor glial cell line-derived neurotrophic factor family receptor alpha4 impairs thyroid calcitonin production in young mice","volume":"147","author":"Lindfors","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.omto.2021.01.012_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ckj\/sfv011","article-title":"Calcitonin, the forgotten hormone: does it deserve to be forgotten?","volume":"8","author":"Felsenfeld","year":"2015","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.omto.2021.01.012_bib19","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/clinchem\/45.8.1347","article-title":"Hormonal control of calcium homeostasis","volume":"45","author":"Mundy","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.omto.2021.01.012_bib20","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1038\/sj.onc.1202848","article-title":"The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein","volume":"18","author":"Bongarzone","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.omto.2021.01.012_bib21","unstructured":"The Human Protein Atlas. GFRA4. https:\/\/www.proteinatlas.org\/search\/gfra4."},{"key":"10.1016\/j.omto.2021.01.012_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/ERC-16-0393","article-title":"Differential roles of RET isoforms in medullary and papillary thyroid carcinomas","volume":"24","author":"Lian","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.omto.2021.01.012_bib23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1349-7006.2009.01484.x","article-title":"Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis","volume":"101","author":"Koga","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omto.2021.01.012_bib24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.01.012_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omto.2021.01.012_bib26","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1089\/dna.2017.3821","article-title":"Downregulation of microRNA-483-5p Promotes Cell Proliferation and Invasion by Targeting GFRA4 in Hirschsprung\u2019s Disease","volume":"36","author":"Wang","year":"2017","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.omto.2021.01.012_bib27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.01.012_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0896-6273(01)00188-X","article-title":"Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts","volume":"29","author":"Paratcha","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.omto.2021.01.012_bib29","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1038\/sj.onc.1210161","article-title":"The mouse soluble GFRalpha4 receptor activates RET independently of its ligand persephin","volume":"26","author":"Yang","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.omto.2021.01.012_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T\u00a0cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.01.012_bib31","doi-asserted-by":"crossref","unstructured":"Goydel RS, Weber J, Peng H, Qi J, Soden J, Freeth J, Park H, Rader C.J Biol Chem. 2020 May 1;295(18):5995-6006. doi: 10.1074\/jbc.RA120.012791.","DOI":"10.1074\/jbc.RA120.012791"},{"key":"10.1016\/j.omto.2021.01.012_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/HAB-180347","article-title":"Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives","volume":"27","author":"Mayrhofer","year":"2019","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.omto.2021.01.012_bib33","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1101\/gr.155499.113","article-title":"Proteome-wide discovery of mislocated proteins in cancer","volume":"23","author":"Lee","year":"2013","journal-title":"Genome Res."},{"key":"10.1016\/j.omto.2021.01.012_bib34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1089\/dna.2017.3928","article-title":"Demethylation of GFRA4 Promotes Cell Proliferation and Invasion in Hirschsprung Disease","volume":"37","author":"Wang","year":"2018","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.omto.2021.01.012_bib35","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1136\/jmg.40.3.e18","article-title":"Investigation of germline GFRA4 mutations and evaluation of the involvement of GFRA1, GFRA2, GFRA3, and GFRA4 sequence variants in Hirschsprung disease","volume":"40","author":"Borrego","year":"2003","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.omto.2021.01.012_bib36","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.01.012_bib37","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omto.2021.01.012_bib38","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.jmb.2017.08.003","article-title":"Mining Na\u00efve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility","volume":"429","author":"Peng","year":"2017","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omto.2021.01.012_bib39","series-title":"Phage Display: A Laboratory Manual","first-page":"10.11","article-title":"Chapter 10. Selection from Antibody Libraries; Chapter 11. Analysis of Selected Antibodies","author":"Rader","year":"2001"},{"key":"10.1016\/j.omto.2021.01.012_bib40","doi-asserted-by":"crossref","first-page":"W503","DOI":"10.1093\/nar\/gkn316","article-title":"IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis","volume":"36","author":"Brochet","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omto.2021.01.012_bib41","doi-asserted-by":"crossref","first-page":"D301","DOI":"10.1093\/nar\/gkp946","article-title":"IMGT\/3Dstructure-DB and IMGT\/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T\u00a0cell receptors, MHC, IgSF and MhcSF","volume":"38","author":"Ehrenmann","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omto.2021.01.012_bib42","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1172\/JCI24185","article-title":"Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display","volume":"115","author":"Payne","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2021.01.012_bib43","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T\u00a0cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2021.01.012_bib44","first-page":"56027","article-title":"Isolation and Culture of Primary Mouse Keratinocytes from Neonatal and Adult Mouse Skin","volume":"125","author":"Li","year":"2017","journal-title":"J.\u00a0Vis. Exp."}],"container-title":["Molecular Therapy Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770521000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770521000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:34:45Z","timestamp":1784723685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770521000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":44,"alternative-id":["S2372770521000139"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2021.01.012","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive T\u00a0cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2021.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}